Table 1.
Baseline characteristics of the 57 patients included in this study and the 614 patients included in the 223Ra-dichloride group of the ALSYMPCA trial [12]
| Characteristic | This study | ALSYMPCA trial |
|---|---|---|
| Age (years), median (range) | 74 (48–90) | 71 (49–90) |
| Age >75 years, n (%) | 23 (40) | 171 (28) |
| Any prior use of docetaxel, n (%) | ||
| Yes | 32 (56) | 352 (57) |
| No | 25 (44) | 262 (43) |
| Total alkaline phosphatase level (U/L), n (%) | ||
| <220 | 28 (54) | 348 (57) |
| ≥220 | 24 (46) | 266 (43) |
| 0–130 | 16 (28) | NR |
| 130–260 | 15 (26) | NR |
| 260–1,000 | 21 (3) | NR |
| >1,000 | 4 (7) | NR |
| Eastern Cooperative Oncology Group performance status, n (%) | ||
| 0 | 1 (2) | 165 (27) |
| 1 | 34 (60) | 371 (60) |
| ≥2 | 22 (38) | 77 (13) |
| Extent of bone disease (EOBD category), n (%) | ||
| <6 metastases (EOBD1) | 10 (18) | 100 (16) |
| 6–20 metastases (EOBD2) | 16 (28) | 262 (43) |
| >20 metastases (EOBD3) | 17 (30) | 195 (32) |
| Superscan (EOBD4) | 14 (25) | 54 (9) |
| Baseline blood investigations, median (range) | ||
| Haemoglobin (g/dL) | 12.1 (7.6–14.6) | 12.2 (8.5–15.7) |
| Total alkaline phosphatase (U/L) | 240 (58–2,805) | 211 (32–6,431) |
| Prostate-specific antigen (μg/L) | 223.9 (0.61–1,747) | 146 (4–6,026) |
| Other treatments, n (%) | ||
| Adjuvant therapy during 223Ra-dichloride | 50 (88) | NR |
| Antiandrogen | 40 (70) | NR |
| Steroids | 34 (60) | NR |
| External beam radiation therapy | 12 (21) | 99 (16)a |
| Abiraterone | 7 (12) | NR |
| Enzalutamide | 7 (12) | NR |
| Bisphosphonates | NR | 250 (41)b |
NR not reported
aWithin 12 weeks of therapy
b''Current use'